

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

PPMX and ASKA Pharmaceutical Sign Joint Research Agreement to Aim to Create New Antibody Drugs

TOKYO, November 5, 2025 - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), and Perseus Proteomics Inc. (Head Office: Chuo-ku, Tokyo/President &CEO: Takuya Yokokawa, hereinafter “PPMX”) have entered into a joint research agreement to create new antibody drugs using PPMX's proprietary antibody technologies with the aim of developing new therapeutic drugs for specific disease areas. Details are shown in the attachment.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp



PPMX and ASKA Pharmaceutical Sign Joint Research Agreement to Aim to Create New Antibody Drugs

TOKYO, November 5, 2025 – Perseus Proteomics Inc. (Head Office: Chuo-ku, Tokyo/President &CEO: Takuya Yokokawa, hereinafter “PPMX”) and ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), are pleased to announce that they have entered into a joint research agreement to create new antibody drugs using PPMX's proprietary antibody technologies with the aim of developing new therapeutic drugs for specific disease areas.

Perseus Proteomics utilizes a unique screening method that combines the hybridoma method, a conventional antibody production technique, with the phage display method using highly diverse human and camel antibody libraries and the proprietary ICOS method* to produce optimal antibodies for even more challenging drug targets. This unique screening method enables the production of optimal antibodies for even the most challenging drug targets.

Since its establishment in 1920, ASKA has been engaged in new drug-focused business as a specialty pharma company, focusing on three key therapeutic areas: internal medicine (gastroenterology and thyroid), obstetrics and gynecology, and urology. Recently, ASKA has been expanding its pipeline by promoting drug discovery research to address unmet medical needs, in addition to its existing efforts.

About Perseus Proteomics Inc.

Based on the protein expression and antibody production technologies developed at Laboratories for Systems Biology and Medicine, Research Center for Advanced Science and Technology, the University of Tokyo (LSBM) was established in 2001 with the aim of utilizing antibodies in medicine. PPMX is engaged in three main businesses: drug discovery, antibody research support including antibody production and sequence analysis, and antibody and reagent sales. PPMX is developing innovative antibody drugs to address unmet medical needs, including cancer.

URL : <https://www.ppmx.com/en/>

*ICOS method: Isolation of antigen/antibody Complexes through Organic Solvent method. A technique to obtain antibodies that recognize the three-dimensional structure of proteins on cell surface using living cells. This is a unique screening method using organic solvents, which enables us to obtain efficiently unique antibodies with high specificity from approximately 100 billion phage antibody libraries.

About ASKA Pharmaceutical Co., Ltd.

Based on its corporate philosophy, "Contribute toward the improvement of people's health and progress in society through the development of innovative products," ASKA specializes in three key therapeutic areas: internal medicine (gastroenterology and thyroid), obstetrics and gynecology, and urology, and is engaged in business centered on new drugs with the aim of becoming a competitive specialty pharma company.

ASKA will solidify its position as a competitive specialty pharma company and contribute to people's health to meet the changing needs of society, while building on our contributions through pharmaceutical products.

URL: <https://www.aska-pharma.co.jp/>

For inquiries regarding this release, please contact:

Administrative Department,
Perseus Proteomics Inc.

E-mail: ir@ppmx.com

Corporate Planning Department,
ASKA Pharmaceutical Co., Ltd..

E-mail: kouhou@aska-pharma.co.jp